IngredientsTaxillus sutchuenensis (Lecomte) Danser is a hemiparasitic flowering plant belonging to the family Loranthaceae, order Santalales. Its full accepted scientific name is Taxillus sutchuenensis (Lecomte) Danser. The Latin name Taxillus sutchuenensis was first published in the Bulletin du Jardin botanique de Buitenzorg in 1929. The species epithet sutchuenensis refers to its close association with Sichuan (Szechuan) province in China, and accordingly it is often called Sichuan mistletoe or Chinese taxillus twig. This plant is known as "Sang Ji Sheng" in traditional Chinese medicine.
T. sutchuenensis is closely related to — and frequently discussed alongside — Taxillus chinensis (DC.) Danser, which is the most widely referenced species within the same genus under the collective drug name Taxilli Herba (桑寄生, Sangjisheng). Both species are hemiparasites that extract water and nutrients from their host trees while retaining some capacity for photosynthesis. Taxillus sutchuenensis (Lecomte) Danser (Loranthaceae) is a semi-parasitic plant that is widely distributed in South China and is important in Chinese traditional medicine. The hosts of T. sutchuenensis include species in the families Aceraceae, Anacardiaceae, and Euphorbiaceae, as well as Styrax japonicus (Styracaceae), Castanea spp. (Fagaceae), and Quercus spp. (Fagaceae). Notably, the metabolic activity of the parasitic plant itself also differs depending on the diversity of the host, which produces different chemical constituents.
In taxonomic and pharmacognostic literature, T. sutchuenensis is listed as one of several official or semi-official source plants for the drug Taxilli Herba. T. chinensis is included in the 2020 Edition of the Chinese Pharmacopoeia as Taxilli Herba. Herba Taxilli is the dry leafy stem and branch of Taxillus sutchuenensis (Lecomte) Danser, which grows on various trees and shrubs. In traditional medicine contexts, the two species (T. chinensis and T. sutchuenensis) have been used near-interchangeably for the same indications, and the drug monograph often covers both plants.
T. sutchuenensis is a shrub that colonizes mountain slopes, forests, and valleys; it has a parasitic nature and lives off various host trees. Branches and stems are cylindrical, more than 30 cm long and 0.5–1 cm in diameter, with branches or branch scars. The surface is grayish-brown or reddish-brown, with longitudinal striations and numerous small, light-colored lenticels protruding from the skin. Young branches may have brown fine hairs and leaves, and villi can be seen. Leaves are oblong-elliptic or ovate, opposite or alternate, with young leaves covered in fine villi, or the back of the leaves densely covered with rusty hairs which are easily detached and appear leathery. The texture is hard with an uneven fracture surface, and the herb has no odor and a bland taste. T. sutchuenensis parasitizes host Styrax japonicus at the canopy, and the aerial adventitious roots extend down the host trunk.
Owing to similarities in morphology and difficulty in sample collection, T. chinensis is often confused with other plants, such as Scurrula parasitica L., Taxillus balansae (Lecomte) Danser, and Scurrula parastica var. graciliflora. In addition to macroscopic morphological identification, microscopic, physical and chemical, and secondary metabolite analyses, as well as genetic identification, provide more accurate evidence.
The use of Sang Ji Sheng in East Asian medicine is ancient. It is a relatively practical and common Chinese herbal medicine, which first appeared in the Shennong Ben Cao Jing in the late Western Han Dynasty (around 100 BCE). Known as "Sangjisheng" in Chinese, it is a member of the family Loranthaceae, with the traditional functions of "dispelling wind dampness, strengthening bones and muscles, and preventing miscarriage." Since the Eastern Han dynasty, it has been used for the treatment of rheumatoid arthritis, arthralgia, threatened abortion, and hypertension.
Classical texts continued to elaborate on its uses across dynasties. The "Southern Yunnan Materia Medica" (AD 1436) records that T. chinensis parasitizing Styphnolobium japonicum (L.) Schott can treat intestinal sub-wind blood syndrome, hemorrhoids, and blood leakage; T. chinensis parasitizing Morus alba L. can treat muscle and collateral obstruction and wind-cold-dampness arthralgia. This indicates an early recognition by classical herbalists that the host tree on which the parasite grew could influence its medicinal properties.
In TCM theory, the herb is classified as entering the Liver and Kidney meridians. Its canonical TCM functions include tonifying the Liver and Kidney, expelling wind-dampness, and consolidating bone and sinew. In traditional clinical application, Taxillus chinensis has the functions of tonifying the liver and kidney, dispelling rheumatism, strengthening bones and muscles, nourishing blood, preventing miscarriage, and lowering blood pressure.
T. chinensis is traditionally used to treat various diseases, including joint swelling and pain, rheumatism, threatened abortion, stroke, and hypertension. It is used for relief from rheumatic conditions, reinforcement of the liver and kidneys, strengthening of tendons and bones, and prevention of abortions.
The primary traditional preparation is a water decoction of the dried twigs and leaves. Classic books of herbal medicine record the use of branches and leaves as decoctions administered orally, with dosages of 15–30 g cited in Bei Ji Qian Jin Yao Fang for rheumatism, and 10–15 g for gynecological diseases cited in Yi Xue Zhong Zhong Can Xi Lu and Tai Ping Sheng Hui He Ji.
Beyond simple decoctions, the herb has historically been incorporated into complex multi-herb formulas. T. chinensis is traditionally used to treat various diseases including rheumatism, threatened abortion, and hypertension. The Duhuo Jisheng, Qisang Yigan, and Sangge Jiangzhi pills, among other preparations, have been widely used in traditional prescriptions. To enhance efficacy, T. chinensis is often used in combination with other drugs, such as Gastrodia rhizoma, Smilacis glabrae Rhizome, Eucommiae cortex, and Polygoni multiflori Radix.
T. chinensis is also used as raw material for making parasitism tea in China, which is a traditional Chinese food healthcare tea, and is exported to nearly 30 countries in Southeast Asia. As a commercial herbal commodity, the dried herb is marketed internationally in cut, sliced, and powdered concentrate forms.
Taxillus sutchuenensis, commonly known as Sichuan mistletoe, is a hemi-parasitic plant traditionally revered in East Asian herbal medicine. For centuries, this botanical has held a significant place in Chinese, Korean, and other regional medicinal systems. T. sutchuenensis, a species of mistletoe commonly found in East Asia, has a long history of use in traditional Chinese medicine (TCM).
The phytochemistry of the Taxilli Herba drug class — which directly encompasses T. sutchuenensis — has been studied with growing comprehensiveness. To date, approximately 110 compounds, including flavonoids, phenolic acids, phenylpropanoids, tannins, glycosides, amino acids, and nucleosides, have been identified in T. chinensis. Flavonoids are considered the most vital bioactive ingredients in T. chinensis. Phytochemical analysis has revealed that Taxilli Herba contains multiple chemical constituents such as flavonoids, phenolic acids, volatiles, terpenoid derivatives, and other chemical constituents based on previous literature.
Flavonoids are the dominant and most pharmacologically studied compound class. Flavonoids were recommended as the inspection indicators in the quality evaluation reports, mainly focusing on the quantitative determination of quercetin, quercitrin, and avicularin. Key individual flavonoids identified in T. sutchuenensis and closely related preparations include:
A 2007 phytochemical study of T. sutchuenensis specifically (cited as Chen JT, Feng F, Journal of Chinese Medicinal Materials) characterized several of these flavonoid constituents directly from the species. Quercetin also had antioxidant, anti-inflammatory, and antiproliferative activities, and quercetin might be an important bioactive compound in T. sutchuenensis.
A study conducted on a 50% methanol extract of Taxilli Herba from Morus alba L. revealed the presence of five tannins, including glucogallin, procyanidin B2, procyanidin B1, procyanidin C1, and procyanidin B2-3′-O-gallate. Catechin (d-catechin) has also been reported.
Diarylheptanoids are a structurally distinctive class found in T. sutchuenensis. In conclusion, flavonoids and diarylheptanoids were responsible for the anti-HCV constitution of Taxilli Herba. The specific compound (3S)-3-hydroxy-1,7-bis(4-hydroxy-phenyl)-6E-hepten-5-one was isolated and characterized from T. sutchuenensis extracts as an inhibitor of the HCV NS3 serine protease.
Additional compounds documented across the Taxilli Herba source species include oleanolic acid, beta-amyrin, lupeol, mesoinositol, myristic acid, various amino acids, nucleosides, and terpenoids. Because of its rich flavonoids, alkaloids, terpenoids, polysaccharides, organic acids, and other functional substances, it has become one of the important medicinal plants in traditional Chinese medicine.
A significant feature of T. sutchuenensis chemistry is that its constituent profile varies depending on the host tree. The metabolic activity of the parasitic plant itself also differs depending on the diversity of the host, which produces different chemical constituents. This means that Taxilli Herba samples collected from different host trees may exhibit substantially different phytochemical profiles and, potentially, different biological activities — a quality control challenge acknowledged by researchers.
The anti-inflammatory activity of T. sutchuenensis and its major constituent quercetin has been studied primarily at the cellular level. The ethyl-acetate fraction decreased LPS-induced NO production and the expression of iNOS and COX-2 in RAW264.7 cells. Downregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are recognized mechanisms through which flavonoid-rich plant extracts reduce inflammatory signaling.
At a more specific molecular level, quercetin from the broader Taxilli Herba complex has been shown to operate through the JAK/STAT/HIF-1α pathway. Quercetin caused inhibition of glucose, lactate, lactate dehydrogenase, pyruvate, and adenosine triphosphate, and increased pyruvate dehydrogenase expression in MH7A cells. It was confirmed that quercetin may inhibit energy metabolism and inflammatory factor secretion in MH7A cells through JAK1/STAT3/HIF-1α signaling. Quercetin's action on multiple target molecules and pathways makes it a promising treatment for cartilage injury in rheumatoid arthritis. By reducing joint inflammation, improving joint metabolic homeostasis, and decreasing immune system activation energy, quercetin inhibits the JAK1/STAT3/HIF-1α signaling pathway to improve disease status.
Among all fractions tested, the ethyl-acetate (EA) fraction showed the highest TEAC and DPPH radical scavenging activities, and the EA fraction also had the highest polyphenol and flavonoid content. The antioxidant capacity is attributed primarily to the dense polyphenolic content of the extract. The experimental data indicated that T. sutchuenensis is a potent antioxidant medicinal plant, and such efficacy may be mainly attributed to its polyphenolic compounds. The general mechanism involves direct radical scavenging and metal chelation by the phenolic hydroxyl groups of quercetin and related flavonoids.
A study aimed to isolate active compounds from T. sutchuenensis to inhibit hepatitis C virus (HCV) NS3 protease activity. Under the guidance of bioassay, 10 compounds were isolated from the EtOAc extract fraction, which were identified as inhibitors of HCV NS3 protease, and a broad degree of anti-HCV activity was observed. The most active compounds were kaempferol-3,7-bisrhamnoside (IC₅₀: 19.4 μM) and (3S)-3-hydroxy-1,7-bis(4-hydroxy-phenyl)-6E-hepten-5-one (IC₅₀: 28.7 μM). HCV NS3 is a serine protease essential for viral polyprotein processing; its inhibition prevents viral replication. These inhibitors of HCV NS3 protease might serve as potential candidates of anti-HCV agents.
The anti-inflammatory, antioxidant, and hypertensive pharmacological effects are closely related to traditional applications. Primarily, it inhibits the production of inflammatory factors and reduces mitochondrial oxidative stress and cyclin degradation.
Research on closely related T. chinensis has identified potent inhibition of fatty acid synthase (FAS), an enzyme central to lipogenesis. Parasitic loranthus, known as "Sang Ji Sheng," has been used to treat rheumatoid arthralgia, threatened abortion, and hypertension, and has also been applied as an anti-obesity herbal medicine. One study showed that the extract of Taxillus chinensis (DC.) Danser inhibited FAS with an IC₅₀ value of 0.48 μg/ml, which is the lowest reported among all reported inhibitors. The flavonoid avicularin was identified as a key constituent responsible for this FAS inhibition. While this mechanism is documented for T. chinensis, T. sutchuenensis contains avicularin as well.
It is essential to note that the vast majority of available scientific evidence is preclinical in nature (in vitro cell studies and animal experiments). Well-controlled human clinical trials specifically studying T. sutchuenensis as a defined intervention are very limited. The following sections state the evidence type and its limitations explicitly.
Evidence type: In vitro (cell culture).
The most directly relevant published study on T. sutchuenensis itself is a 2012 in vitro investigation published in The American Journal of Chinese Medicine. T. sutchuenensis (Lecomte) Danser is described as a special folk medicinal plant in Taiwan. The study evaluated the antioxidant, anti-inflammatory, and antiproliferative activities of the aqueous-ethanol extract from T. sutchuenensis (AETS) and its fractions. TEAC, DPPH radicals, total phenolic compounds, total flavonoid content, inhibition of NO production in LPS-induced RAW264.7 cells, and inhibition of cancer cell proliferation were tested.
Key results included: Among all fractions, the ethyl-acetate (EA) fraction showed the highest TEAC and DPPH radical scavenging activities and had the highest polyphenol and flavonoid content; the EA fraction also decreased LPS-induced NO production and the expression of iNOS and COX-2 in RAW264.7 cells. The antiproliferative activities of the aqueous/ethanol extract and fractions were studied in vitro using A549 cells; EA fractions had the highest antiproliferative activity with an IC₅₀ of 454.38 ± 1.48 μg/ml.
Limitations: This was entirely an in vitro study using cell lines. No animal or human evidence was generated. The findings establish biological plausibility but cannot be extrapolated to therapeutic use in humans without further study.
Evidence type: In vitro (biochemical enzyme assay).
A 2016 study (published 2017, Natural Product Research) isolated compounds from T. sutchuenensis specifically to test against HCV NS3 serine protease. The study aimed to isolate active compounds from T. sutchuenensis to inhibit HCV NS3 protease activity; under the guidance of bioassay, 10 compounds were isolated from the EtOAc extract fraction, identified as inhibitors of HCV NS3 protease. The most active compounds were kaempferol-3,7-bisrhamnoside (19.4 μM) and (3S)-3-hydroxy-1,7-bis(4-hydroxy-phenyl)-6E-hepten-5-one (28.7 μM). Flavonoids and diarylheptanoids were responsible for the anti-HCV constitution of Taxilli Herba.
Limitations: This is a biochemical enzyme inhibition assay — the lowest tier of pharmacological evidence. No cellular antiviral activity or animal or human data exist for this use. IC₅₀ values in enzyme assays do not predict clinical efficacy.
Evidence type: Traditional use; preclinical (molecular pharmacology of constituent quercetin).
The use of Sang Ji Sheng for joint pain and rheumatic conditions is one of its longest-standing traditional applications. One of the most celebrated applications of Taxillus sutchuenensis was in remedies for joint and muscle discomfort, especially those attributed to "wind-damp" conditions in traditional Chinese medicine. Modern research has examined the mechanisms by which its key constituent, quercetin, might support this use at the preclinical level: quercetin's action on multiple target molecules and pathways makes it a promising treatment for cartilage injury in rheumatoid arthritis; by reducing joint inflammation, improving joint metabolic homeostasis, and decreasing immune system activation energy, quercetin inhibits the JAK1/STAT3/HIF-1α signaling pathway to improve disease status.
The traditional multi-herb formula Duhuo Jisheng Wan, which includes T. chinensis/T. sutchuenensis, is one of the most commonly studied TCM preparations for knee osteoarthritis and rheumatic pain. However, the clinical evidence for the formula as a whole cannot be attributed to the Taxillus component alone.
Limitations: No clinical trials have been conducted evaluating T. sutchuenensis as a standalone intervention for any rheumatological condition in human subjects. Evidence at this stage remains in vitro and attributable to isolated constituents, not the whole herb.
Evidence type: Traditional use; animal (preclinical); constituent-level data.
Hypertension is among the classical indications for Sang Ji Sheng. Some traditional applications include promoting blood circulation, alleviating hypertension, and preventing vascular disorders, but these claims are rooted in TCM theory rather than modern biomedical understanding. At the preclinical level, quercetin from the Taxilli Herba complex has been tested in animal models: published data indicate that quercetin administered intragastrically at 30 mg/kg body weight to renal hypertensive rats demonstrated blood-pressure-lowering effects (cited in the 2022 comprehensive review). Some in vitro and animal studies suggest that mistletoe extracts may have vasodilatory, antihypertensive, or antioxidant effects, but there is little direct evidence from controlled clinical trials supporting its efficacy for circulatory health in humans. Overall, the use of Taxillus sutchuenensis for circulatory support is best characterized as traditional, with limited scientific corroboration.
Limitations: Animal and constituent-level data only. No randomized controlled trials have been published that specifically evaluate T. sutchuenensis extract in hypertensive human subjects.
Evidence type: Traditional use; systems pharmacology modeling; preclinical.
Sang Ji Sheng has been used for centuries to prevent threatened abortion and support pregnancy. Data mining research has shown that Cuscutae Semen and Herba Taxilli were frequently prescribed for threatened abortion treatment and were always used in combination as an herb pair, indicating the key role of these two herbs in threatened abortion treatment. A 2020 systems pharmacology study (Biomed Res Int) examined the mechanism of the Tusizi–Sangjisheng herb pair, identifying potential molecular targets relevant to uterine function, but this was a computational network pharmacology model rather than a clinical trial.
Limitations: Evidence is traditional and computational. No controlled human trials have verified the safety or efficacy of T. sutchuenensis for threatened abortion. Given reported embryotoxicity concerns in the genus (see Safety section), this application warrants caution pending further study.
Evidence type: In vitro (cell lines) only.
The antiproliferative activities of the aqueous/ethanol extract and fractions were studied in vitro using A549 cells (human lung adenocarcinoma), and the EA fractions had the highest antiproliferative activity with an IC₅₀ of 454.38 ± 1.48 μg/ml. Additional pharmacological data on the broader T. chinensis/T. sutchuenensis complex suggest anticancer potential in cell line models. Related research on the pharmacology of T. chinensis shows it may have good effects on the treatment of cancer, among other conditions, and has high clinical value.
Limitations: All anticancer evidence is from in vitro cell line studies. IC₅₀ values from cell culture experiments frequently do not translate to in vivo efficacy due to bioavailability, metabolism, and tissue distribution constraints. No animal models or human trials exist for this application.
Evidence type: Preclinical (in vitro and animal), attributed primarily to constituent quercetin and the broader Taxilli Herba complex.
Pharmacological studies have demonstrated that T. chinensis possesses anti-inflammatory, antioxidant, anticancer, antimicrobial, antiviral, diuretic, antihypertensive, antihyperglycemic, and other properties. Antihyperglycemic effects have been noted in preclinical models, but no clinical trials are available for T. sutchuenensis as a defined intervention for diabetes or blood glucose management.
Evidence type: In vitro.
For the first time, researchers found that Taxillus chinensis has a good antibacterial effect, with the ethyl acetate extract having the best effect. Additionally, 4-indolecarbaldehyde was identified as an active component with a good broad-spectrum antibacterial effect. These findings are from laboratory-based susceptibility studies. No clinical evidence exists.
Based on the totality of traditional use and preclinical data, T. sutchuenensis is associated with the following body systems and health areas:
In traditional and clinical practice, T. sutchuenensis is administered in several forms:
For research purposes, animal studies have used quercetin from the Taxilli Herba complex at doses such as 30 mg/kg body weight (intragastric) in renal hypertensive rat models, demonstrating blood pressure reduction. In in vitro antiviral studies, the IC₅₀ values of the most active isolated compounds (kaempferol-3,7-bisrhamnoside and a diarylheptanoid) were 19.4 μM and 28.7 μM, respectively.
No standardized human clinical dosage has been established for T. sutchuenensis as a standalone dietary supplement in any published regulatory or clinical trial context. Bioassessments should consider the advisable effective dose, frequency of administration, and treatment duration.
T. chinensis exhibits both hepatotoxicity and embryotoxicity. This is a notable finding documented in the 2022 peer-reviewed comprehensive review published in Chinese Medicine (Springer/BMC). The hepatotoxic potential has been attributed to certain constituents of Taxilli Herba and has been noted in preclinical assessments. Many active components of T. chinensis have not yet been fully investigated, nor have their mechanisms of action elucidated.
Reported embryotoxicity within the Taxillus genus is of significant concern given the herb's traditional use specifically for threatened abortion, which creates an apparent paradox that has been acknowledged in the scientific literature. T. chinensis exhibits both hepatotoxicity and embryotoxicity, according to the 2022 comprehensive review. The underlying mechanisms are not yet fully characterized.
Because the chemical composition of T. sutchuenensis varies by host species, preparations from different host trees may have substantially different activity and safety profiles. Clinical applications must be specified; otherwise, it may be misused, and the desired therapeutic effect will not be achieved. Misidentification with other morphologically similar Loranthaceae species is a recognized quality control concern. Owing to similarities in morphology and difficulty in sample collection, T. chinensis is often confused with other plants, such as Scurrula parasitica L. and related species.
Currently, research on T. chinensis is in the preliminary stages, and further research is required to understand the active compounds present and mechanisms of action. Reports on botany, traditional applications, or toxicology are minimal; therefore, these aspects must be reviewed. No formal toxicological monograph or maximum tolerated dose data for T. sutchuenensis in humans was identified in the peer-reviewed literature. Safety information currently relies on traditional use patterns and limited animal toxicology.
No peer-reviewed clinical data on specific drug–herb interactions for T. sutchuenensis were identified in the sources available. Given that quercetin is a significant constituent and is a known inhibitor/modulator of certain cytochrome P450 enzymes in other contexts, interactions with drugs that are substrates of CYP enzymes are plausible but uncharacterized for this specific herb. The justification for several uses of Taxillus sutchuenensis is largely traditional, grounded in symptomatic treatment approaches rather than modern pharmacological evidence. While some phytochemical studies have identified antioxidant and anti-inflammatory properties in related mistletoe species, there is little to no direct scientific research specifically validating certain uses.
Research on T. chinensis (and by extension T. sutchuenensis) is in the preliminary stages, and further research is required to understand the active compounds present and mechanisms of action. The literature is mainly based on the identification of chemical components; however, the components have not been thoroughly analyzed, and only simple pharmacological activity studies have been performed, mainly focused on crude extracts and their characteristic compounds, especially quercetin.
The most pressing research gaps are: (1) the absence of randomized controlled trials in humans for any clinical indication; (2) the need for standardized extract preparations with defined constituent ratios; (3) formal characterization of hepatotoxic and embryotoxic mechanisms; (4) systematic pharmacokinetic studies in humans; and (5) investigation of host-dependent chemical variation and its impact on safety and efficacy.
The demand for T. chinensis is constantly rising in the global herbal market due to its immense therapeutic potential, and scientific interest is accelerating — but the evidence base remains far behind traditional claims.
Health conditions that Taxillus sutchuenensis may help support.
Body systems that Taxillus sutchuenensis may help support.
Go back